Scienture has a total of 16 patents globally, out of which none have been granted. Of these 16 patents, more than 75% patents are active. The USA is where Scienture has filed the maximum number of patents. Parallelly, the USA seems to be the main focused R&D center of Scienture and is also the origin country of the firm.
Scienture was founded in the year 2019 by Shankar Hariharan. The company is a pharmaceutical research firm used to focus on drug screening.
Do read about some of the most popular patents of Scienture which have been covered by us in this article and also you can find Scienture patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Scienture patent portfolio.
How many patents does Scienture have?
Scienture has a total of 16 patents globally. These patents belong to 4 unique patent families. Out of 16 patents, 12 patents are active.
How Many Patents did Scienture File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
How many Scienture patents are Alive/Dead?
Worldwide Patents
How Many Patents did Scienture File in Different Countries?
Countries in which Scienture Filed Patents
| Country | Patents |
| Canada | 3 |
| United States Of America | 3 |
| Europe (EPO) | 3 |
| Japan | 3 |
Where are Research Centres of Scienture Patents Located?
The R&D Centres of patents filed by Scienture is in the US.
List of Scienture Patents
| Scienture Patents | Title |
| US20230218582A1 | Losartan Liquid Formulations And Methods Of Use |
| US20230137010A1 | Long-Acting Apomorphine Formulations And Injectors For Therapeutic Delivery Of The Same |
| US20230043204A1 | Dihydroergotamine Mesylate Formulations And Pre-Filled Injectors For Therapeutic Delivery Of The Same |
| EP4004138A4 | Dihydroergotamine Mesylate Formulations And Pre-Filled Injectors For Therapeutic Delivery Of The Same |
| EP4138783A1 | Long-Acting Bupivacaine Microsphere Formulations |
| EP4132475A2 | Long-Acting Apomorphine Formulations And Injectors For Therapeutic Delivery Of The Same |
| CA3180971A1 | Long-Acting Bupivacaine Microsphere Formulations |
| CA3179866A1 | Long-Acting Apomorphine Formulations And Injectors For Therapeutic Delivery Of The Same |
| CA3151950A1 | Dihydroergotamine Mesylate Formulations And Pre-Filled Injectors For Therapeutic Delivery Of The Same |
| JP2023522987A | Long-Acting Bupivacaine Microsphere Formulation |
| JP2023522134A | Long-Acting Apomorphine Formulations And Injectors For Their Therapeutic Delivery |
| JP2023507890A | Dihydroergotamine Mesylate Formulations And Prefilled Syringes For Their Therapeutic Delivery |
| WO2022076746A1 | Losartan Liquid Formulations And Methods Of Use |
| WO2021207737A3 | Long-Acting Apomorphine Formulations And Injectors For Therapeutic Delivery Of The Same |
| WO2021216928A1 | Long-Acting Bupivacaine Microsphere Formulations |
| WO2021133744A1 | Dihydroergotamine Mesylate Formulations And Pre-Filled Injectors For Therapeutic Delivery Of The Same |
What are Scienture’s key innovation segments?
What Technologies are Covered by Scienture?
The chart below distributes patents filed by Scienture